Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.15
HBIO's Cash to Debt is ranked higher than
71% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. HBIO: 1.15 )
HBIO' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.15

Equity to Asset 0.71
HBIO's Equity to Asset is ranked higher than
82% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. HBIO: 0.71 )
HBIO' s 10-Year Equity to Asset Range
Min: 0.68   Max: 0.93
Current: 0.71

0.68
0.93
Interest Coverage 1.61
HBIO's Interest Coverage is ranked lower than
55% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.78 vs. HBIO: 1.61 )
HBIO' s 10-Year Interest Coverage Range
Min: 1.61   Max: 9999.99
Current: 1.61

1.61
9999.99
F-Score: 5
Z-Score: 3.06
M-Score: -2.45
WACC vs ROIC
14.19%
3.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.09
HBIO's Operating margin (%) is ranked higher than
67% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.34 vs. HBIO: 6.09 )
HBIO' s 10-Year Operating margin (%) Range
Min: -33.77   Max: 19.85
Current: 6.09

-33.77
19.85
Net-margin (%) 2.17
HBIO's Net-margin (%) is ranked higher than
67% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. HBIO: 2.17 )
HBIO' s 10-Year Net-margin (%) Range
Min: -163.11   Max: 17.58
Current: 2.17

-163.11
17.58
ROE (%) 2.45
HBIO's ROE (%) is ranked higher than
66% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. HBIO: 2.45 )
HBIO' s 10-Year ROE (%) Range
Min: -679.29   Max: 22.98
Current: 2.45

-679.29
22.98
ROA (%) 1.73
HBIO's ROA (%) is ranked higher than
67% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.71 vs. HBIO: 1.73 )
HBIO' s 10-Year ROA (%) Range
Min: -211.43   Max: 16.39
Current: 1.73

-211.43
16.39
ROC (Joel Greenblatt) (%) 26.25
HBIO's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.05 vs. HBIO: 26.25 )
HBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -166.58   Max: 38.14
Current: 26.25

-166.58
38.14
Revenue Growth (3Y)(%) -3.60
HBIO's Revenue Growth (3Y)(%) is ranked higher than
61% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HBIO: -3.60 )
HBIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.7   Max: 11.4
Current: -3.6

-23.7
11.4
EBITDA Growth (3Y)(%) -28.80
HBIO's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HBIO: -28.80 )
HBIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.8   Max: 29.1
Current: -28.8

-28.8
29.1
EPS Growth (3Y)(%) -68.70
HBIO's EPS Growth (3Y)(%) is ranked higher than
50% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. HBIO: -68.70 )
HBIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.7   Max: 171.4
Current: -68.7

-68.7
171.4
» HBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HBIO Guru Trades in Q1 2014

Jim Simons 584,574 sh (+19.5%)
Zeke Ashton 285,000 sh (+9.62%)
Arnold Van Den Berg 190,130 sh (unchged)
Chuck Royce 767,100 sh (unchged)
John Hussman 930,000 sh (unchged)
» More
Q2 2014

HBIO Guru Trades in Q2 2014

Jim Simons 740,400 sh (+26.66%)
Zeke Ashton 300,000 sh (+5.26%)
Arnold Van Den Berg 190,130 sh (unchged)
Chuck Royce 767,100 sh (unchged)
John Hussman 930,000 sh (unchged)
» More
Q3 2014

HBIO Guru Trades in Q3 2014

Chuck Royce 774,800 sh (+1%)
Arnold Van Den Berg 190,130 sh (unchged)
John Hussman 930,000 sh (unchged)
Zeke Ashton 271,600 sh (-9.47%)
Jim Simons 632,100 sh (-14.63%)
» More
Q4 2014

HBIO Guru Trades in Q4 2014

Arnold Van Den Berg 191,225 sh (+0.58%)
Chuck Royce 774,800 sh (unchged)
John Hussman 908,000 sh (-2.37%)
Jim Simons 599,719 sh (-5.12%)
Zeke Ashton 50,000 sh (-81.59%)
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Arnold Van Den Berg 2013-12-31 Add 105.68%0.04%$3.758 - $5.07 $ 5.5126%190130
Arnold Van Den Berg 2013-09-30 New Buy0.05%$3.6 - $4.28 $ 5.5140%92440
John Hussman 2011-12-31 Add 33.33%0.02%$2.92 - $3.75 $ 5.5168%1000000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 121.60
HBIO's P/E(ttm) is ranked higher than
69% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.60 vs. HBIO: 121.60 )
HBIO' s 10-Year P/E(ttm) Range
Min: 3.71   Max: 144.21
Current: 121.6

3.71
144.21
Forward P/E 43.10
HBIO's Forward P/E is ranked higher than
76% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.95 vs. HBIO: 43.10 )
N/A
PE(NRI) 93.50
HBIO's PE(NRI) is ranked higher than
71% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.30 vs. HBIO: 93.50 )
HBIO' s 10-Year PE(NRI) Range
Min: 3.69   Max: 481
Current: 93.5

3.69
481
P/B 1.90
HBIO's P/B is ranked higher than
84% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.67 vs. HBIO: 1.90 )
HBIO' s 10-Year P/B Range
Min: 0.63   Max: 2.28
Current: 1.9

0.63
2.28
P/S 1.70
HBIO's P/S is ranked higher than
85% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. HBIO: 1.70 )
HBIO' s 10-Year P/S Range
Min: 0.51   Max: 2.6
Current: 1.7

0.51
2.6
PFCF 79.80
HBIO's PFCF is ranked higher than
76% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.01 vs. HBIO: 79.80 )
HBIO' s 10-Year PFCF Range
Min: 4.96   Max: 126.28
Current: 79.8

4.96
126.28
POCF 43.15
HBIO's POCF is ranked higher than
71% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. HBIO: 43.15 )
HBIO' s 10-Year POCF Range
Min: 4.6   Max: 84.19
Current: 43.15

4.6
84.19
EV-to-EBIT 50.26
HBIO's EV-to-EBIT is ranked higher than
70% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.45 vs. HBIO: 50.26 )
HBIO' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 106
Current: 50.26

4.7
106
Shiller P/E 22.70
HBIO's Shiller P/E is ranked higher than
93% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 155.01 vs. HBIO: 22.70 )
HBIO' s 10-Year Shiller P/E Range
Min: 8.95   Max: 41.33
Current: 22.7

8.95
41.33
Current Ratio 3.78
HBIO's Current Ratio is ranked higher than
85% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. HBIO: 3.78 )
HBIO' s 10-Year Current Ratio Range
Min: 1.97   Max: 11.53
Current: 3.78

1.97
11.53
Quick Ratio 2.62
HBIO's Quick Ratio is ranked higher than
84% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. HBIO: 2.62 )
HBIO' s 10-Year Quick Ratio Range
Min: 1.15   Max: 10.71
Current: 2.62

1.15
10.71
Days Inventory 107.50
HBIO's Days Inventory is ranked higher than
78% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.97 vs. HBIO: 107.50 )
HBIO' s 10-Year Days Inventory Range
Min: 40.88   Max: 274.71
Current: 107.5

40.88
274.71
Days Sales Outstanding 54.22
HBIO's Days Sales Outstanding is ranked higher than
87% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.21 vs. HBIO: 54.22 )
HBIO' s 10-Year Days Sales Outstanding Range
Min: 47.14   Max: 104.4
Current: 54.22

47.14
104.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.19
HBIO's Price/Net Current Asset Value is ranked higher than
83% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. HBIO: 9.19 )
HBIO' s 10-Year Price/Net Current Asset Value Range
Min: 1.89   Max: 9.75
Current: 9.19

1.89
9.75
Price/Tangible Book 5.45
HBIO's Price/Tangible Book is ranked higher than
77% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. HBIO: 5.45 )
HBIO' s 10-Year Price/Tangible Book Range
Min: 1.65   Max: 7.17
Current: 5.45

1.65
7.17
Price/DCF (Projected) 1.19
HBIO's Price/DCF (Projected) is ranked higher than
93% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. HBIO: 1.19 )
HBIO' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.36
Current: 1.19

0.48
1.36
Price/Median PS Value 1.48
HBIO's Price/Median PS Value is ranked higher than
64% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. HBIO: 1.48 )
HBIO' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 4.09
Current: 1.48

0.61
4.09
Price/Graham Number 4.59
HBIO's Price/Graham Number is ranked higher than
78% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.66 vs. HBIO: 4.59 )
HBIO' s 10-Year Price/Graham Number Range
Min: 0.67   Max: 113.75
Current: 4.59

0.67
113.75
Earnings Yield (Greenblatt) 2.00
HBIO's Earnings Yield (Greenblatt) is ranked higher than
69% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. HBIO: 2.00 )
HBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 21.2
Current: 2

0.9
21.2
Forward Rate of Return (Yacktman) -16.31
HBIO's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.36 vs. HBIO: -16.31 )
HBIO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.3   Max: 18.4
Current: -16.31

-16.3
18.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HBI.Germany,
Harvard Bioscience, Inc. a Delaware corporation began in 1901. The Company is a developer, manufacturer and marketer of specialized products, like apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories. It has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain and sales facilities in France and Canada. It sells its products to researchers in over 100 countries mainly through its sales organization, catalog, website, distributors like GE Healthcare, Thermo Fisher Scientific Inc. and VWR, and via its field sales organization. Today, its broad product range is generally targeted towards two application areas; ADMET testing and molecular biology and liquid handling. ADMET Testing - The ADMET testing identifies compounds that have toxic side effects or undesirable physiological or pharmacological properties. It has products that its customers use to help their researchers conduct experiments on cells, tissues, organs and animals. The Company sells these products under the brand names including Harvard Pumps, Harvard Apparatus, Denville, Biochrom, Warner Instruments, BTX, KD Scientific, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, and CMA Microdialysis. These products are mainly scientific instruments such as spectrophotometers and plate readers that analyze light to detect and quantify molecular and cellular processes or apparatus such as gel electrophoresis units. The Company's end-user customers are mainly research scientists at pharmaceutical and biotechnology companies, universities and government laboratories, including the U.S. National Institutes of Health, or NIH. The Company's academic customers have included colleges and universities such as Baylor University, Cambridge University, Harvard University, Johns Hopkins University, Massachusetts Institute of Technology, Yale University and the University of Texas - MD Anderson Center. The Company's pharmaceutical and biotechnological customers have included pharmaceutical companies and research laboratories such as Amgen, Inc., AstraZeneca plc, Genentech, Inc. and Johnson & Johnson. It competes with several companies that provide instruments for life science research including, Amaxa GmbH, Becton Dickinson, Eppendorf AG, Kent Scientific Corporation, Razel Scientific Instruments, Inc., Ugo Basile, Danaher Corporation, Bio-Rad Laboratories, Inc., MDS Analytical Technologies, PerkinElmer, Inc. and Thermo Fisher Scientific, Inc. The Company is not subject to direct governmental regulation other than the laws and regulations generally applicable to businesses in the domestic and foreign jurisdictions in which it operates.
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 
Harvard Bioscience, Inc. Schedules Fourth Quarter 2008 Conference Call for February 26, 2009 Feb 09 2009 

More From Other Websites
Harvard Bioscience posts 4Q loss Feb 26 2015
Harvard Bioscience posts 4Q loss Feb 26 2015
Harvard Bioscience Fourth Quarter 2014 Non-GAAP EPS Increases 100% Versus Fourth Quarter 2013 on... Feb 26 2015
Harvard Bioscience Fourth Quarter 2014 Non-GAAP EPS Increases 100% Versus Fourth Quarter 2013 on... Feb 26 2015
Q4 2014 Harvard Bioscience Inc Earnings Release - Before Market Open Feb 26 2015
'Pathetic and disgraceful' — NYT's ex-editor Jill Abramson on Silicon Valley gender inequality Feb 24 2015
The Massachusetts schools with the best SAT scores in 2014 (BBJ DataCenter) Feb 24 2015
A biospherian, three Harvard grads and an (offline) matchmaker made this week’s list of most-read... Feb 21 2015
BuzzFeed acquires the GIF masters at GoPop to head up its app team (Video) Feb 20 2015
How three Harvard students created Her Campus, a media company profitable from day one Feb 18 2015
Harvard Bioscience Appoints Ryan Atienza to Vice President of Sales at Its Denville Scientific... Feb 18 2015
Harvard Bioscience Appoints Ryan Atienza to Vice President of Sales at Its Denville Scientific... Feb 18 2015
Penn Law finds new dean from within its own ranks Feb 17 2015
Harvard Bioscience Schedules Fourth Quarter and Year-End 2014 Conference Call for February 26 at... Feb 13 2015
Harvard Bioscience Schedules Fourth Quarter and Year-End 2014 Conference Call for February 26 at... Feb 13 2015
The BBJ's Five Things: Dodd-Frank's sting; Roxbury retrofit; Biotech's slowdown; NFL looks to Boston Feb 10 2015
Here's a partial list of operations that are closing or altering schedules Tuesday Feb 09 2015
Harvard study says Dodd-Frank hurting small banks Feb 09 2015
Md. health-tech firm going public next week with plans to raise $613 million Feb 06 2015
Fashion Project secures $7.2M in Series A funding Feb 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK